{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:22Z","timestamp":1792788382231,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Shanghai","award":["grant no. 21ZR1450900"],"award-info":[{"award-number":["grant no. 21ZR1450900"]}]},{"name":"the Shanghai Science and Technology Planning Project","award":["grant no. 21Y11907000"],"award-info":[{"award-number":["grant no. 21Y11907000"]}]},{"name":"the Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center","award":["grant no. SHDC12019X34"],"award-info":[{"award-number":["grant no. SHDC12019X34"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["grant no. 81772762"],"award-info":[{"award-number":["grant no. 81772762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian clear cell carcinoma (OCCC) is a rare pathological histotype in ovarian cancer, while the survival rate of advanced OCCC (Stage III-IV) is substantially lower than that of the advanced serous ovarian cancer (OSC), which is the most common histotype. The goal of this study was to identify high-risk OCCC by comparing OSC and OCCC, with investigating potential risk and prognosis markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients diagnosed with ovarian cancer from 2009 to 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) Program. Logistic and Cox regression models were used to identify risk and prognostic factors in high-risk OCCC patients. Cancer-specific survival (CSS) and overall survival (OS) were assessed using Kaplan-Meier curves. Furthermore, Cox analysis was employed to build a nomogram model. The performance evaluation results were displayed using the C-index, calibration plots, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). Immunohistochemically approach was used to identify the expression of the novel target (GPC3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the Cox analysis for advanced OCCC, age (45\u201365 years), tumor numbers (total number of in situ\/malignant tumors for patient), T3-stage, bilateral tumors, and liver metastases could be defined as prognostic variables. Nomogram showed good predictive power and clinical practicality. Compared with OSC, liver metastases had a stronger impact on the prognosis of patients with OCCC. T3-stage, positive distant lymph nodes metastases, and lung metastases were risk factors for developing liver metastases. Chemotherapy was an independent prognostic factor for patient with advanced OCCC, but had no effect on CSS in patients with liver metastases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0656), while surgery was significantly related with better CSS in these patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0041). GPC3 expression was detected in all tissue sections, and GPC3 staining was predominantly found in the cytoplasm and membranes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advanced OCCC and OCCC with liver metastases are two types of high-risk OCCC. The constructed nomogram exhibited a satisfactory survival prediction for patients with advanced OCCC. GPC3 immunohistochemistry is expected to accumulate preclinical evidence to support the inclusion of GPC3 in OCCC targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-024-01435-y","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T06:01:24Z","timestamp":1717221684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study"],"prefix":"10.1186","volume":"17","author":[{"given":"Tingwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangdi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"publisher","first-page":"104001","DOI":"10.1016\/j.ebiom.2022.104001","volume":"79","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Bi M, Guo H, Li M. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. EBioMedicine. 2022;79:104001.","journal-title":"EBioMedicine"},{"issue":"1","key":"1435_CR2","first-page":"1","volume":"27","author":"W Chen","year":"2015","unstructured":"Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015;27(1):1.","journal-title":"Chin J Cancer Res"},{"key":"1435_CR3","doi-asserted-by":"crossref","unstructured":"Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A et al. Hereditary Ovarian Cancer: towards a cost-effective Prevention Strategy. Int J Environ Res Public Health. 2022;19(19).","DOI":"10.3390\/ijerph191912057"},{"issue":"3","key":"1435_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ygyno.2021.06.033","volume":"162","author":"A Gadducci","year":"2021","unstructured":"Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD. Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2021;162(3):741\u201350.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1435_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109(3):370\u20136.","journal-title":"Gynecol Oncol"},{"key":"1435_CR6","doi-asserted-by":"publisher","first-page":"874037","DOI":"10.3389\/fonc.2022.874037","volume":"12","author":"SI Kim","year":"2022","unstructured":"Kim SI, Ha HI, Eoh KJ, Lim J, Won YJ, Lim MC. Trends in the incidence and survival rates of primary ovarian Clear Cell Carcinoma compared to ovarian serous carcinoma in Korea. Front Oncol. 2022;12:874037.","journal-title":"Front Oncol"},{"key":"1435_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semcancer.2019.10.025","volume":"61","author":"S Khalique","year":"2020","unstructured":"Khalique S, Lord CJ, Banerjee S, Natrajan R. Translational genomics of ovarian clear cell carcinoma. Semin Cancer Biol. 2020;61:121\u201331.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1435_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/path.4516","volume":"236","author":"MS Anglesio","year":"2015","unstructured":"Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236(2):201\u20139.","journal-title":"J Pathol"},{"issue":"3","key":"1435_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10147-020-01625-w","volume":"25","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Takenaka M, Kawabata A, Yanaihara N, Okamoto A. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. Int J Clin Oncol. 2020;25(3):425\u201331.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1435_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1435_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/IGC.0000000000000178","volume":"24","author":"K Suzuki","year":"2014","unstructured":"Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, et al. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer. 2014;24(7):1181\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"1435_CR12","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.21037\/atm-20-3022a","volume":"8","author":"EP Samartzis","year":"2020","unstructured":"Samartzis EP, Labidi-Galy SI, Moschetta M, Uccello M, Kalaitzopoulos DR, Perez-Fidalgo JA, et al. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review. Ann Transl Med. 2020;8(24):1712.","journal-title":"Ann Transl Med"},{"issue":"2","key":"1435_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-22-1159","volume":"83","author":"CK Wang","year":"2023","unstructured":"Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, et al. MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian Cancer tumorigenesis. Cancer Res. 2023;83(2):251\u201363.","journal-title":"Cancer Res"},{"key":"1435_CR14","doi-asserted-by":"publisher","first-page":"798173","DOI":"10.3389\/fonc.2021.798173","volume":"11","author":"H Liu","year":"2021","unstructured":"Liu H, Zhang Z, Chen L, Pang J, Wu H, Liang Z. Next-generation sequencing reveals a very low prevalence of deleterious mutations of homologous recombination repair genes and homologous recombination Deficiency in Ovarian Clear Cell Carcinoma. Front Oncol. 2021;11:798173.","journal-title":"Front Oncol"},{"issue":"9","key":"1435_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.6004\/jnccn.2016.0122","volume":"14","author":"RJ Morgan Jr","year":"2016","unstructured":"Morgan RJ Jr., Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134\u201363.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 6","key":"1435_CR16","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","journal-title":"Ann Oncol"},{"issue":"2","key":"1435_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ygyno.2005.12.038","volume":"102","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102(2):285\u201391.","journal-title":"Gynecol Oncol"},{"key":"1435_CR18","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.canep.2021.102045","volume":"75","author":"N Pavlidis","year":"2021","unstructured":"Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045.","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"1435_CR19","doi-asserted-by":"publisher","first-page":"e1238542","DOI":"10.1080\/2162402X.2016.1238542","volume":"5","author":"S Suzuki","year":"2016","unstructured":"Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, et al. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology. 2016;5(11):e1238542.","journal-title":"Oncoimmunology"},{"key":"1435_CR20","doi-asserted-by":"crossref","unstructured":"Ukai M, Yokoi A, Yoshida K, Suzuki S, Shibata K, Kikkawa F et al. Extracellular miRNAs as predictive biomarkers for glypican-3-Derived peptide vaccine Therapy Response in Ovarian Clear Cell Carcinoma. Cancers (Basel). 2021;13(3).","DOI":"10.3390\/cancers13030550"},{"issue":"12","key":"1435_CR21","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1093\/annonc\/mdx525","volume":"28","author":"A Oseledchyk","year":"2017","unstructured":"Oseledchyk A, Leitao MM Jr., Konner J, O\u2019Cearbhaill RE, Zamarin D, Sonoda Y, et al. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and end results Cohort Study, 2000\u20132013. Ann Oncol. 2017;28(12):2985\u201393.","journal-title":"Ann Oncol"},{"issue":"3","key":"1435_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/1933719117715126","volume":"25","author":"C Borner","year":"2018","unstructured":"Borner C, Scheerer C, Buschow R, Chiantera V, Sehouli J, Mechsner S. Pain mechanisms in Peritoneal diseases might be partially regulated by Estrogen. Reprod Sci. 2018;25(3):424\u201334.","journal-title":"Reprod Sci"},{"issue":"1","key":"1435_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00404-019-05358-8","volume":"301","author":"M Kralickova","year":"2020","unstructured":"Kralickova M, Lagana AS, Ghezzi F, Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet. 2020;301(1):1\u201310.","journal-title":"Arch Gynecol Obstet"},{"key":"1435_CR24","doi-asserted-by":"crossref","unstructured":"Tamura R, Yoshihara K, Enomoto T. Therapeutic strategies focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma. Cancers (Basel). 2022;14(9).","DOI":"10.3390\/cancers14092125"},{"key":"1435_CR25","doi-asserted-by":"crossref","unstructured":"Dozen A, Shozu K, Shinkai N, Ikawa N, Aoyama R, Machino H et al. Tumor suppressive role of the PRELP Gene in Ovarian Clear Cell Carcinoma. J Pers Med. 2022;12(12).","DOI":"10.3390\/jpm12121999"},{"key":"1435_CR26","doi-asserted-by":"publisher","first-page":"940601","DOI":"10.3389\/fonc.2022.940601","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Xiu L, Ma M, Seery S, Lou X, Li K, et al. Developing and validating a prognostic nomogram for ovarian clear cell carcinoma patients: a retrospective comparison of lymph node staging schemes with competing risk analysis. Front Oncol. 2022;12:940601.","journal-title":"Front Oncol"},{"issue":"3","key":"1435_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ygyno.2019.03.243","volume":"153","author":"H Machida","year":"2019","unstructured":"Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153(3):589\u201396.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1435_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrc3497","volume":"13","author":"JP de Magalhaes","year":"2013","unstructured":"de Magalhaes JP. How ageing processes influence cancer. Nat Rev Cancer. 2013;13(5):357\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1435_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ygyno.2017.04.021","volume":"146","author":"JG Cohen","year":"2017","unstructured":"Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, et al. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol. 2017;146(1):146\u201352.","journal-title":"Gynecol Oncol"},{"key":"1435_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejrad.2018.10.021","volume":"109","author":"HL Joo","year":"2018","unstructured":"Joo HL, Shin YR, Rha SE, Park CS, Shim DJ, Kim K. Preoperative discrimination of tumour stage in clear cell carcinoma of the ovary using computed tomography and magnetic resonance imaging. Eur J Radiol. 2018;109:19\u201326.","journal-title":"Eur J Radiol"},{"issue":"1","key":"1435_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2018.04.567","volume":"150","author":"D Nasioudis","year":"2018","unstructured":"Nasioudis D, Mastroyannis SA, Albright BB, Haggerty AF, Ko EM, Latif NA. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: patterns of use and outcomes. Gynecol Oncol. 2018;150(1):14\u20138.","journal-title":"Gynecol Oncol"},{"key":"1435_CR32","doi-asserted-by":"publisher","first-page":"862944","DOI":"10.3389\/fonc.2022.862944","volume":"12","author":"L Wu","year":"2022","unstructured":"Wu L, Shi S, Sun H, Zhang H. Tumor size is an independent prognostic factor for stage I ovarian clear cell carcinoma: a large Retrospective Cohort Study of 1,000 patients. Front Oncol. 2022;12:862944.","journal-title":"Front Oncol"},{"issue":"1","key":"1435_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0090-8258(03)00004-0","volume":"89","author":"MA Merideth","year":"2003","unstructured":"Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89(1):16\u201321.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1435_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ygyno.2018.06.022","volume":"150","author":"K Deng","year":"2018","unstructured":"Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecol Oncol. 2018;150(3):460\u20135.","journal-title":"Gynecol Oncol"},{"key":"1435_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2022.12.023","volume":"170","author":"RM Kahn","year":"2023","unstructured":"Kahn RM, McMinn E, Yeoshoua E, Boerner T, Zhou Q, Iasonos A, et al. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: going to the next level - A Memorial Sloan Kettering Cancer Center study. Gynecol Oncol. 2023;170:46\u201353.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1435_CR36","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.21873\/anticanres.15111","volume":"41","author":"M Friedrich","year":"2021","unstructured":"Friedrich M, Friedrich D, Kraft C, Rogmans C. Multimodal Treatment of Primary Advanced Ovarian Cancer. Anticancer Res. 2021;41(7):3253\u201360.","journal-title":"Anticancer Res"},{"issue":"12","key":"1435_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11912-021-01128-5","volume":"23","author":"A Laine","year":"2021","unstructured":"Laine A, Sims TT, Le Saux O, Ray-Coquard I, Coleman RL. Treatment perspectives for ovarian Cancer in Europe and the United States: initial therapy and platinum-sensitive recurrence after PARP inhibitors or Bevacizumab Therapy. Curr Oncol Rep. 2021;23(12):148.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"1435_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00404-018-5006-z","volume":"299","author":"SG Vitale","year":"2019","unstructured":"Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299(2):299\u2013315.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"1435_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/IGC.0000000000000612","volume":"28","author":"M Dessole","year":"2018","unstructured":"Dessole M, Petrillo M, Lucidi A, Naldini A, Rossi M, De Iaco P, et al. Quality of life in women after pelvic exenteration for Gynecological malignancies: a multicentric study. Int J Gynecol Cancer. 2018;28(2):267\u201373.","journal-title":"Int J Gynecol Cancer"},{"key":"1435_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22\u201333.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1435_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/sj.bjc.6603116","volume":"94","author":"M Takano","year":"2006","unstructured":"Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94(10):1369\u201374.","journal-title":"Br J Cancer"},{"key":"1435_CR42","doi-asserted-by":"crossref","unstructured":"Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian Cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13).","DOI":"10.3390\/ijerph19138113"},{"issue":"2","key":"1435_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00404-020-05952-1","volume":"304","author":"Q Chen","year":"2021","unstructured":"Chen Q, Wang S, Lang JH. Clinical characteristics and prognostic factors of stage IC ovarian clear cell carcinoma: a Surveillance, Epidemiology, and end results (SEER) analysis. Arch Gynecol Obstet. 2021;304(2):521\u20139.","journal-title":"Arch Gynecol Obstet"},{"key":"1435_CR44","doi-asserted-by":"crossref","unstructured":"Ivy SP, Beumer JH. Ovarian Cancer survival and chemotherapy dosing, body Mass Index, and body surface area. JAMA Oncol. 2015;1(6).","DOI":"10.1001\/jamaoncol.2015.1926"},{"key":"1435_CR45","doi-asserted-by":"crossref","unstructured":"Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E et al. Applications of Proteomics in Ovarian Cancer: Dawn of a new era. Proteomes. 2022;10(2).","DOI":"10.3390\/proteomes10020016"},{"key":"1435_CR46","doi-asserted-by":"publisher","first-page":"ed62","DOI":"10.3332\/ecancer.2017.ed62","volume":"11","author":"AS Lagana","year":"2017","unstructured":"Lagana AS, La Rosa VL, Rapisarda AM, Platania A, Vitale SG. Psychological impact of fertility preservation techniques in women with gynaecological cancer. Ecancermedicalscience. 2017;11:ed62.","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"1435_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12885-020-06828-y","volume":"20","author":"D Liu","year":"2020","unstructured":"Liu D, Cai J, Gao A, Wang Z, Cai L. Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival. BMC Cancer. 2020;20(1):320.","journal-title":"BMC Cancer"},{"issue":"1","key":"1435_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ygyno.2015.05.004","volume":"138","author":"A Ditto","year":"2015","unstructured":"Ditto A, Martinelli F, Bogani G, Lorusso D, Carcangiu M, Chiappa V, et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol. 2015;138(1):78\u201382.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1435_CR49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in patients with Advanced Ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332.","journal-title":"N Engl J Med"},{"issue":"9","key":"1435_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jmig.2022.05.016","volume":"29","author":"MC Di Donna","year":"2022","unstructured":"Di Donna MC, Sozzi G, Cucinella G, Giallombardo V, Gallotta V, Uccella S, et al. Laparoscopic ultra-radical Lymph Node Debulking using Yasargil Clamps for Gynecological malignancies: results from a large, Multicenter, Retrospective Analysis. J Minim Invasive Gynecol. 2022;29(9):1083\u201391.","journal-title":"J Minim Invasive Gynecol"},{"issue":"1","key":"1435_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ygyno.2020.10.028","volume":"160","author":"N Bizzarri","year":"2021","unstructured":"Bizzarri N, du Bois A, Fruscio R, De Felice F, De Iaco P, Casarin J, et al. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecol Oncol. 2021;160(1):56\u201363.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1435_CR52","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.3802\/jgo.2018.29.e19","volume":"29","author":"H Yamazaki","year":"2018","unstructured":"Yamazaki H, Todo Y, Shimada C, Takeshita S, Minobe S, Okamoto K, et al. Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma. J Gynecol Oncol. 2018;29(2):e19.","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"1435_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2174\/1568009623666230209121732","volume":"23","author":"F Aliyuda","year":"2023","unstructured":"Aliyuda F, Moschetta M, Ghose A, Sofia Rallis K, Sheriff M, Sanchez E, et al. Advances in ovarian Cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. 2023;23(6):433\u201346.","journal-title":"Curr Cancer Drug Targets"},{"key":"1435_CR54","doi-asserted-by":"crossref","unstructured":"Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M et al. Recent insights into PARP and Immuno-Checkpoint inhibitors in epithelial ovarian Cancer. Int J Environ Res Public Health. 2022;19(14).","DOI":"10.3390\/ijerph19148577"},{"issue":"6","key":"1435_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm-22-1045","volume":"10","author":"J Wu","year":"2022","unstructured":"Wu J, You Y, Zhuang R, Guo X, Zhang C, Zhang Q, et al. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report. Ann Transl Med. 2022;10(6):387.","journal-title":"Ann Transl Med"},{"issue":"5","key":"1435_CR56","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.13704","volume":"73","author":"T Koopman","year":"2018","unstructured":"Koopman T, van der Vegt B, Dijkstra M, Bart J, Duiker E, Wisman GBA, et al. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology. 2018;73(5):852\u201363.","journal-title":"Histopathology"},{"issue":"3","key":"1435_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ygyno.2004.05.055","volume":"94","author":"H Tanabe","year":"2004","unstructured":"Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, et al. Overexpression of HER-2\/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2004;94(3):735\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1435_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89\u201397.","journal-title":"Gastroenterology"},{"issue":"10","key":"1435_CR59","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/febs.12126","volume":"280","author":"J Filmus","year":"2013","unstructured":"Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013;280(10):2471\u20136.","journal-title":"FEBS J"},{"issue":"2","key":"1435_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13402-017-0364-2","volume":"41","author":"M Montalbano","year":"2018","unstructured":"Montalbano M, Rastellini C, McGuire JT, Prajapati J, Shirafkan A, Vento R, et al. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma. Cell Oncol (Dordr). 2018;41(2):169\u201384.","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"1435_CR61","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.trecan.2018.09.004","volume":"4","author":"N Li","year":"2018","unstructured":"Li N, Gao W, Zhang YF, Ho M. Glypicans as Cancer therapeutic targets. Trends Cancer. 2018;4(11):741\u201354.","journal-title":"Trends Cancer"},{"key":"1435_CR62","doi-asserted-by":"publisher","first-page":"9653194","DOI":"10.1155\/2017\/9653194","volume":"2017","author":"AT Reiner","year":"2017","unstructured":"Reiner AT, Tan S, Agreiter C, Auer K, Bachmayr-Heyda A, Aust S, et al. EV-Associated MMP9 in high-Grade Serous Ovarian Cancer is preferentially localized to annexin V-Binding EVs. Dis Markers. 2017;2017:9653194.","journal-title":"Dis Markers"},{"issue":"1","key":"1435_CR63","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1186\/s12885-019-6176-1","volume":"19","author":"W Zhang","year":"2019","unstructured":"Zhang W, Peng P, Ou X, Shen K, Wu X. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. BMC Cancer. 2019;19(1):1095.","journal-title":"BMC Cancer"},{"key":"1435_CR64","doi-asserted-by":"crossref","unstructured":"Lucidi A, Buca D, Ronsini C, Tinari S, Bologna G, Buca D et al. Role of Extracellular vesicles in epithelial ovarian Cancer: a systematic review. Int J Mol Sci. 2020;21(22).","DOI":"10.3390\/ijms21228762"},{"issue":"6","key":"1435_CR65","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/modpathol.2009.40","volume":"22","author":"D Maeda","year":"2009","unstructured":"Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009;22(6):824\u201332.","journal-title":"Mod Pathol"},{"issue":"3","key":"1435_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/pgp.0b013e31802d692c","volume":"26","author":"S Stadlmann","year":"2007","unstructured":"Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. 2007;26(3):341\u20134.","journal-title":"Int J Gynecol Pathol"},{"key":"1435_CR67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.humpath.2020.01.002","volume":"98","author":"K Wiedemeyer","year":"2020","unstructured":"Wiedemeyer K, Kobel M, Koelkebeck H, Xiao Z, Vashisht K. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. Hum Pathol. 2020;98:56\u201363.","journal-title":"Hum Pathol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01435-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-024-01435-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01435-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T07:02:41Z","timestamp":1717225361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-024-01435-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1186\/s13048-024-01435-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was built on open access databases. The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Shanghai First Maternity and Infant Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}